CELLECTAR BIOSCIENCES, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On June 12, 2023, the Company issued a press release providing a research and development program summary. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

Item 8.01. Other Events.

On June 12, 2023, the Company issued a press release that included updated guidance related to its Waldenstrom's macroglobulinemia (WM) CLOVER-WaM pivotal trial. The company now expects to release top-line data from the WM CLOVER-WaM trial in the second half of 2023.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits



Number     Title
  99.1       Press release, dated June 12, 2023, entitled, "Cellectar Provides a
           Research and Development Program Summary"
104        Cover Page Interactive Data File (formatted as Inline XBRL and
           contained in Exhibit 101)

© Edgar Online, source Glimpses